​

Funding Round

Series B - KalVista Pharmaceuticals

Series B - KalVista Pharmaceuticals

Investment Firm

Overview

KalVista Pharmaceuticals is an ophthalmology company focused on developing drugs for the treatment of diabetic macular edema (DME).

Announced Date

Jul 22, 2015

Funding Type

Series B

Highlights

Location

United States, North America

Social

Investor Lead

RA Capital Management

RA Capital Management

RA Capital Management is a convertible_note and debt and early_stage_venture and late_stage_venture and post_ipo and private_equity and seed and venture firm.

Participant Investors

5

Investor Name
Participant InvestorRA Capital Management
Participant InvestorLongwood Fund
Participant InvestorNovo Holdings
Participant InvestorVenrock
Participant InvestorSV Health Investors

Round Details and Background

KalVista Pharmaceuticals raised $33000000 on 2015-07-22 in Series B

KalVista Pharmaceuticals is an ophthalmology company focused on developing drugs for the treatment of diabetic macular edema (DME).

Company Funding History

5

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Dec 27, 2022
Post-IPO Equity - KalVista Pharmaceuticals
-58.0M
Feb 15, 2024
Post-IPO Equity - KalVista Pharmaceuticals
-160.1M
Jul 22, 2015
Series B - KalVista Pharmaceuticals
5-33.0M
Aug 23, 2011
Series A - KalVista Pharmaceuticals
2-13.2M

Recent Activity

There is no recent news or activity for this profile.